CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment
about
Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit allInsights into CYP2B6-mediated drug-drug interactionsMight ART Adherence Estimates Be Improved by Combining Biomarker and Self-Report Data?African genetic diversity: implications for human demographic history, modern human origins, and complex disease mappingExpanding the Antimalarial Drug Arsenal-Now, But How?CYP2B6: new insights into a historically overlooked cytochrome P450 isozymeChemokine (C-C motif) receptor 5 -2459 genotype in patients receiving highly active antiretroviral therapy: race-specific influence on virologic successComparative description of haplotype structure and genetic diversity of MDR1 (ABCB1) in HIV-positive and HIV-negative populations.Cytochrome P450 2B6 genetic variants are associated with plasma nevirapine levels and clinical response in HIV-1 infected Kenyan women: a prospective cohort study.PharmGKB summary: Efavirenz pathway, pharmacokineticsPresence of lamivudine or emtricitabine is associated with reduced emergence of nonnucleoside reverse transcriptase inhibitor mutations in an efavirenz-based intermittent antiretroviral treatment regimen.Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation.Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment.An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS PatientsIndividualization of antiretroviral therapy.Bioactivation of chlorpyrifos by CYP2B6 variants.Analysis of pharmacogenetic traits in two distinct South African populationsPharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevanceImpact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patientsCYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy.Clinical and genetic modifiers of long-term survival in heart failure.The impact of pharmacogenetics on HIV therapy.The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosisPrevalence and genetic variants of G6PD deficiency among two Malagasy populations living in Plasmodium vivax-endemic areas.Cytochrome P450 pharmacogenetics in African populations.Pharmacogenetics of antiretroviral therapy.Pharmacogenetics of CYP2B6, CYP2A6 and UGT2B7 in HIV treatment in African populations: focus on efavirenz and nevirapine.The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine.PharmGKB summary: very important pharmacogene information for CYP2B6.Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique.Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study.Human cytochrome P450 2B6 genetic variability in Botswana: a case of haplotype diversity and convergent phenotypes.
P2860
Q24609011-766B7F5C-678B-488B-9064-C2C48563344AQ28078857-6508804C-5B5F-4D79-8E59-5F29E1AC54B5Q28555028-01FC4965-BE90-4438-9C8D-3438123D2C5FQ28748891-84B4F528-3A49-40DB-AA29-9462D7F8B230Q33916111-343884D8-DA6A-4060-9CF7-1D2DBAC49C99Q34824471-FBFB7B49-9D85-4FD4-AA9C-DEB6E88CD5DDQ35043700-80D01A37-4FEF-46D1-8813-345F7F33A9A4Q35295887-707FF502-0875-4A66-98DD-7641597BCEE2Q35426496-AF657A85-EB43-4F73-AB2C-DC4D6FC77F9FQ35706069-C2A1DB05-BA23-4F7E-A56A-5C0048162BA8Q35806160-E06EE2FE-63F7-4173-ADE3-B4E808E61CD9Q35910664-AF784FBC-BFC0-4020-9CFD-1F66FCD0F20EQ36079108-55C22517-DA53-4708-B31D-2B8A01D755F1Q36437792-FDE5F5DD-B786-4D6A-B80C-15228B78567AQ36441423-5A96F4DB-C59D-4C55-AC3B-0EE79C0F1DA6Q36462008-626B1FFB-E0E6-45E0-9DA4-65A67174353DQ36475143-81A2FA0F-7E7B-4150-985C-949C71CD631BQ36657589-4D432A10-33FE-42CC-B7D9-40FD1CD406F3Q36682506-740790FA-C5B0-4AC8-88BE-7D336F8C13A5Q37184431-B2F545B7-56F0-4F2A-9151-B67A8B4416ABQ37278622-CA5138E6-4A6F-46A9-9EEF-8F094A29909BQ37358823-173BA889-4CEE-4F75-9608-DF0F8EF882B6Q37405140-B7C594F7-74F9-4BAF-A422-074D629420ECQ37466856-255D6DCA-E191-44A5-A400-849923129962Q37737972-4EB16396-9DB0-443E-883D-D74FDD635D59Q38099372-F74EB37F-F52A-4E6F-B5DE-1F0B9CDE499DQ38221179-B4F70312-48B4-404F-9378-EE0673841ED0Q38267710-87F20C2F-DD40-40EB-880D-5B21BD28EDFAQ38851258-7D4B46EC-7510-462C-977F-E11D4EB44765Q42725538-A5423C2A-AAB6-4FB8-BBE1-BFDFB2C2BE86Q43217465-CDFE23E3-67C3-4F01-B8F6-C7E404073B1FQ46051781-AF95E8B5-CF79-4EF5-9305-918C47752DD9Q51365463-AD3AB9FA-893C-4210-AF1B-26BABB2F4520
P2860
CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
CYP2B6 983T>C polymorphism is ...... cations for HIV/AIDS treatment
@ast
CYP2B6 983T>C polymorphism is ...... cations for HIV/AIDS treatment
@en
type
label
CYP2B6 983T>C polymorphism is ...... cations for HIV/AIDS treatment
@ast
CYP2B6 983T>C polymorphism is ...... cations for HIV/AIDS treatment
@en
prefLabel
CYP2B6 983T>C polymorphism is ...... cations for HIV/AIDS treatment
@ast
CYP2B6 983T>C polymorphism is ...... cations for HIV/AIDS treatment
@en
P2093
P2860
P921
P1476
CYP2B6 983T>C polymorphism is ...... cations for HIV/AIDS treatment
@en
P2093
Moses J Bockarie
Peter A Zimmerman
Rajeev K Mehlotra
P2860
P304
P356
10.1111/J.1365-2125.2007.02884.X
P407
P577
2007-03-28T00:00:00Z